Journal of Alzheimer's disease : JAD
Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's disease.
Vincenzo Solfrizzi, Bruno P Imbimbo
Published: 202510.1177/13872877251406221
Abstract
BackgroundLecanemab and donanemab are anti-amyloid-β monoclonal antibodies recently approved in the United States and Europe for the treatment of early Alzheimer's disease (AD). Their modest clinical benefit, safety profile, and cost raise debate abo…
Preview only. Read the full abstract at the source